Skip to content

REFERENCE FILE

Dulaglutide

Examine the reference details alongside the questions and dated sources.

Reference details

Status as of

Regulatory category
Approved product
Evidence category
Randomized evidence
Mechanism
GLP-1 receptor agonist fusion protein.
Evidence
Randomized studies.
Limitations
No weight-management indication.
Safety
Not recommended for severe gastroparesis.
Formulation and route
Subcutaneous injection.
Approval scope
Trulicity: specified type 2 diabetes populations.

READING NOTES

Questions for a closer look

Read a dulaglutide outcome sentence with its time expressions highlighted. Locate the event that starts measurement, the occasion when the outcome is assessed and any interval over which experiences are accumulated. Translate each expression into an instruction someone could follow when reviewing a record. Then compare those instructions with the sentence's wording. A question about an experience during an interval differs from a question about a condition at its end. Ask which instruction would produce the reported quantity, without supplying an unreported history. Finish by attaching the relevant timing phrase to your description of the result.

Questions to investigate

  1. Which event starts measurement, and which occasion determines the reported outcome?
  2. Does the wording concern an interval or a condition at its end?
  3. What timing phrase belongs beside the result when I describe it?

Sources for this file

  1. TRULICITYNLM · Checked

MED CONSUMER WATCH · RESEARCH

Read the evidence behind the question.

Browse reference files or follow a study analysis from its question to its limitations.